Omar Eton, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, New York University School of Medicine

Expertise includes: Preclinical to clinical transitions in Oncology; Phase 1,2,3,... oncology drug development from blank concept page to IRB protocol approval and successful trial execution and final published manuscript; Melanoma; Tyrosine kinase inhibitors; Tumor immunology; Endocrine tumors; and GI tumors. Interests include nanocarriers and cutting edge discovery agents heading to the clinic.

Active Staff Privileges
Boston Medical Center

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
02/01/2010 - 01/31/2017 (PI)
Bayer AG

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.
03/10/2010 - 03/09/2013 (PI)
GlaxoSmithKline, Inc.

Expanded Access Program with Nivolumab for subjects with Histologically confirmed Stage III…
12/02/2014 - 12/02/2019 (PI)

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. White PS, Pudusseri A, Lee SL, Eton O. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports. Thyroid. 2017 Sep; 27(9):1201-1205.View Related Profiles. PMID: 28805135.
  2. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother. 2012 Oct; 12(10):1207-15. PMID: 23082737; DOI: 10.1586/ern.12.111;.
  3. Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther. 2010 Oct; 9(10):2844-52. PMID: 20724522; DOI: 10.1158/1535-7163.MCT-10-0299;.
  4. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr; 67(4):945-54. PMID: 20607239; PMCID: PMC3026871; DOI: 10.1007/s00280-010-1377-y;.
  5. Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med. 2010; 8:9. PMID: 20109236; PMCID: PMC2835652; DOI: 10.1186/1479-5876-8-9;.
  6. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, Trepicchio WL, Eton O, Shepherd FA. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009 Aug; 4(8):1002-9. PMID: 19633475; DOI: 10.1097/JTO.0b013e3181aba89f;.
  7. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9. PMID: 19430405; DOI: 10.1097/CMR.0b013e328314b84a;.
  8. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 2; 99(5):734-40. PMID: 18728664; PMCID: PMC2528157; DOI: 10.1038/sj.bjc.6604482;.
  9. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5. PMID: 18626307; DOI: 10.1097/CMR.0b013e3283046146;.
  10. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006 May 1; 106(9):2005-11. PMID: 16565971.
Showing 10 of 50 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 50 publications over 22 distinct years, with a maximum of 8 publications in 1998

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

endocrine cancers (eg thyroid)
gastrointestinal tumors
mutidisciplinary management of melanoma

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map

Eton's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department